Skip to main
HCAT
HCAT logo

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 20%
Hold 70%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc has demonstrated a significant improvement in its earnings power over the past seven years, evidenced by an increase in EBITDA alongside a growing client base. The company benefits from a strong Technology segment, which primarily drives revenue through cloud-based subscriptions and maintenance, as well as a Professional Services segment that adds value through expert implementation and strategic advisory services. Additionally, favorable trends in hospital volumes and an uptake in purchases of Health Catalyst modules from executives suggest potential for continued revenue growth and improving margins, contributing to a positive outlook for the company.

Bears say

Health Catalyst Inc has experienced a slowdown in total revenue growth, raising concerns about its ability to maintain robust revenue and EBITDA expansion in an already highly penetrated Total Addressable Market (TAM) among health systems. Despite the company generating approximately 90% of its revenue from recurring sources, the decline in net dollar-based retention levels indicates potential weaknesses in customer loyalty and satisfaction. Additionally, the failure to provide meaningful ROI could jeopardize the company's relevance in the market, exacerbating these challenges.

HCAT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 20% recommend Buy, 70% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 10 analysts, HCAT has a Hold consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.